Silicone-containing acrylic polymers for transdermal drug delivery compositions

Inactive Publication Date: 2016-02-04
NOVEN PHARMA
View PDF6 Cites 31 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0012]In accordance with other embodiments, there are provided uses of a silicone-containing acrylic polymer in the preparation of a medicament for the tran

Problems solved by technology

Formulating a transdermal drug delivery composition with a high concentration of drug also may undermine the desired physical characteristics of the composition, because many drugs have a plasticizing effect.
Further, a relatively large amount of drug may remain in the composition after use.
On the other hand, the solubility of many drugs in silicone pressure-sensitive adhesives is not sufficient to achieve satisfactory drug loading and drug flux.
Compositions comprising blends of silicone pressure-sensitive adhesives and acrylic pressure-sensitive adhesives suffer from other disadvantages,

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Silicone-containing acrylic polymers for transdermal drug delivery compositions
  • Silicone-containing acrylic polymers for transdermal drug delivery compositions
  • Silicone-containing acrylic polymers for transdermal drug delivery compositions

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0093]Silicone-containing acrylic copolymers are synthesized by copolymerization using methodologies known in the art. For example, acrylic monomers are copolymerized with silicone-containing acrylic monomers in an appropriate solvent, such as ethyl acetate, with an appropriate initiator, such as 2,2′-azobisisobutyronitrile (AIBN), at an appropriate temperature.

[0094]Silicone-containing acrylic copolymer A is prepared as follows: An initial charge containing 9.7 g methyl acrylate (MA), 20.9 g 2-ethylhexyl acrylate (2-EHA), 95.1 g 3-(tris(trimethylsilyloxy)silyl)propyl methacrylate (TRIS), 0.074 g AIBN, and 125.5 g ethyl acetate (solvent) is mixed in a 2-L round bottom flask, which is installed with a thermometer, condenser, stainless steel stirrer, water bath and dropping funnel. Under stirring, the initial charge is heated to 80° C. and allowed to reflux for 15 minutes. Then a mixture of 29.0 g MA, 62.5 g 2-EHA, 285.3 g TRIS, 0.22 g AIBN and 377.0 g ethyl acetate is uniformly added...

example 2

[0097]Methylphenidate was formulated in silicone-containing acrylic polymer B (described above) to prepare a composition comprising 20% methylphenidate and 80% polymer B. Drug flux through human cadaver skin over 24 hours was assessed in vitro. Results as compared to results achieved with the polymer matrix of the commercial Daytrana® product (20% methylphenidate, 80% blend of acrylic pressure-sensitive adhesive polymer and silicone pressure-sensitive adhesive polymer) are shown in FIG. 1 and summarized below.

94 hr FluxFlux Lot #Formulation (SP 9732 Backing)(mcg / cm2 / h)Ratio65654Daytrana9.101.0RN070-132-4L20% MPH + 80% Copolymer B10.481.15

[0098]The results show that the composition based on polymer B achieved a drug flux comparable to that of Daytrana®.

[0099]For comparison, the in vitro flux from a composition prepared with 20% methylphenidate in 80% acrylic pressure-sensitive adhesive (Gelva® 3087) and from Daytrana® are plotted in FIG. 2 and summarized below.

94 hr FluxLot #Formulat...

example 3

[0101]The methylphenidate / polymer B composition described above was applied to a backing and a release liner, and peel force from the release liner was assessed over 4 months. Results as compared to results achieved with the commercial Daytrana® product are shown below.

Peel from Release Liner (g / 0.5″, n = 3)Lot #Formulation (w / w)1M2M3M4MRN056-Freshly made 9.222.439.980.632-4LDaytranaRN070-20% MPH + 80% 23.325.022.418.7132-4LCopolymer B

[0102]The results show that the peel force for the polymer B composition remained stable and low while that of the Daytrana® product increased over time.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Percent by massaaaaaaaaaa
Percent by massaaaaaaaaaa
Percent by massaaaaaaaaaa
Login to view more

Abstract

Described herein are silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions. The polymers are particular suitable for formulating amine drugs, such as amphetamine, methylphenidate, rivastigmine, paroxetine and clonidine.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit under 35 USC §119(e) to U.S. provisional application 62 / 031,325, filed Jul. 31, 2014, the entire contents of which are incorporated herein by reference in their entirety.FIELD[0002]The present invention relates generally to silicone-containing acrylic polymers useful, for example, in transdermal drug delivery compositions, to methods of making and using them, to transdermal drug delivery compositions comprising them, and to methods of making and using such transdermal drug delivery compositions.BACKGROUND[0003]Many factors influence the design and performance of transdermal drug delivery compositions. These include the individual drugs themselves, the physical and chemical characteristics of the compositions' components and their performance and behavior relative to other components, external and environmental conditions during manufacturing and storage, properties of the application site, the desired r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/70A61K9/00A61K31/137A61K31/27A61K31/4168A61K31/4458A61K31/4525C08F230/08
CPCA61K9/7084A61K31/4458A61K9/0014C08F230/08A61K31/27A61K31/4525A61K31/4168A61K31/137A61K9/7061A61P25/22A61P25/24A61P25/26A61P25/28A61P9/12
Inventor LIAO, JUNZHANG, JILINLIU, PUCHUNDINH, STEVEN
Owner NOVEN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap